

Acromegaly without acral anomalies

Mara CARSOTE^{1,2}, Florica SANDRU^{2,3}, Diana Elena RENTE¹, Claudia MEHEDINTU^{2,4}, Stefania ZUGRAVU¹, Corina CHIRITA⁵, Mihai Cristian DUMITRASCU^{2,6}

¹ "C.I. Parhon" National Institute of Endocrinology, Bucharest, Romania

² "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

³ Elias Emergency Hospital, Bucharest, Romania

⁴ "Nicolae Malaxa" Clinical Hospital, Bucharest, Romania

⁵ MedicZone Clinic, Bucharest, Romania

⁶ University Emergency Hospital, Bucharest, Romania

ABSTRACT

Early recognition of a pituitary secretor tumor offers a better prognostic; thus acromegaly might be recognized before the actual clinical picture of acromegaly is detectable. This is a 59-year old, non-smoking female admitted for: post-operative evaluation of acromegaly. The clinical evaluation is non-specific. One year prior she was diagnosed with acromegaly based on cerebral imaging assessment due to intermittent headache. She was treated with cabergoline a few months before neurosurgery was done; post-operative panel showed complete remission of acromegaly. Prompt detection of the disease allowed the early intervention with a very good outcome. The remission of GH excess after neurosurgery depends on tumor size and practical experience of the surgeon. The longer time of high growth hormone levels exposure the higher is the risk of cardio-metabolic and oncologic complications.

Keywords: acromegaly, pituitary tumor, acral, IGF1, GH

INTRODUCTION

Early recognition of a pituitary secretor tumor offers a better prognostic; thus acromegaly might be recognized before the actual clinical picture of acromegaly is detectable (1,2). The longer time of high growth hormone levels exposure the higher is the risk of cardio-metabolic and oncologic complications (3,4).

We aim to introduce a female case with early diagnostic of acromegaly and prompt case management.

CASE PRESENTATION

Admission

This is a 59-year old, non-smoking female admitted for: post-operative evaluation of acromegaly. The fam-

ily medical history is irrelevant. The clinical evaluation is non-specific.

Medical history

She was diagnosed with acromegaly one year prior and initially she was treated with dopamine agonist cabergoline up to 3 mg/week for eleven months, then trans-sphenoidal hypophysectomy was done. The nuclear magnetic resonance examination at diagnostic showed a pituitary adenoma of 12/8/6 millimeter. Her medical history also includes: total hysterectomy for uterine fibroma 7 year prior, surgery for a nasopharyngeal cyst a few weeks before the diagnostic of acromegaly and a recent endoscopic removal of gastric polyp. The acromegaly was detected starting from a

Corresponding author:

Florica Sandru

E-mail: florysandru@yahoo.com

Article History:

Received: 20 December 2021

Accepted: 27 December 2021

cerebral and pituitary magnetic resonance imaging which was performed for non-specific headache.

ASSESSMENTS

The biochemistry panel shows hypercholesterolemia (Table 1).

TABLE 1. Biochemistry panel of 59-year old female known with acromegaly; evaluation after somatotropinoma was removed

Parameter	Value	Normal ranges	Units
Uric acid	4	2.6-6	mg/dl
ALT (Aspartate aminotransferase)	16.7	0-31	U/l
AST (Alanine transaminase)	16.6	0-32	U/l
Conjugated bilirubin	0.22	0-0.5	mg/dl
Total bilirubin	0.5	0.2-1.2	mg/dl
Ionic serum calcium	4.1	3.9-4.9	mg/dl
Total serum calcium	9.5	8.4-10.2	mg/dl
Total cholesterol	245	0-200	mg/dl
Serum phosphorus	4.4	2.3-4.7	mg/dl
Fasting glycaemia	83.1	70-105	mg/dl
HDL-cholesterol	79.3	40-60	mg/dl
LDL-cholesterol	151.8	60-160	mg/dl
Potassium	5	3.5-5.1	mmol/l
Magnesium	2.1	1.6-2.55	mg/dl
Sodium	145	136-145	mmol/l
Total proteins	7.3	6.4-8.3	g/dl
Triglycerides	111	0-149	mg/dl
Urea	25.2	15-50	mg/dl
Creatinine	0.72	0.5-1.2	mg/dl

The endocrine and calcium metabolism assays pointed out remission of acromegaly, a mild vitamin D deficiency (Table 2). The patient started menopause at the age of 43 without hormone replacement therapy. She was treated with cabergoline before surgery for a few months.

TABLE 2 (A+B+C+D+E+F+G). Endocrine and phosphor – calcium metabolic on acromegalic patient 6 weeks after pituitary neurosurgery for a growth hormone producing tumor

A. Thyroid panel

Parameter	Value	Normal ranges	Units
TSH (Thyroid Stimulating Hormone)	0.5	0.5-4.5	µUI/ml
FT4 (Free levothyroxine)	11.44	9-19	pmol/l
ATPO (Anti-thyreoperoxidase antibodies)	0.33	0-5.61	UI/ml
Calcitonin	1.74	5.17-9.82	pg/ml

B. Gonadal axes

Parameter	Value	Normal ranges	Units
FSH(follicle stimulating hormone)	69.56	25.8-134.8	mIU/ml
LH (luteinizing hormone)	30	7.7-58.5	mIU/ml
Estradiol	5	<5-138	pg/ml
Prolactine	0.77	4.79-23.3	ng/ml

C. Calcium metabolism and bone turnover markers

Parameter	Value	Normal ranges	Units
25-hydroxyvitamin D	24.3	30-100	ng/ml
CrossLaps	0.82	0.162-0.436	ng/ml
Osteocalcin	40.5	11-43	ng/ml
P1NP	99.34	14.28-58.92	ng/ml
Parathormone (PTH)	30.07	15-65	pg/ml

D. Adrenal axes

Parameter	Value	Normal ranges	Units
ACTH (Adenocorticotrophic Hormone)	21.38	3-66	pg/ml
Morning plasma cortisol	10.96	4.82-19.5	µg/dl

E. IGF1 (Insulin-like Growth Factor) profile before and after neurosurgery

Parameter	December 2020	March 2021	July 2021	
IGF1 (ng/ml)	400.2	435.4	340.3	
T Trans-sphenoidal hypophysectomy				
Parameter	August 2021	October 2021	Units	Normal ranges
IGF1 (ng/ml)	176.1	186.5	ng/ml	46-238

F. GH profile/24 hours (Growth Hormone) before and after neurosurgery

GH (ng/ml)	December 2020	March 2021	July 2021	Neurosurgery	August 2021	Units
Value 1	1.81	1.63	1.72		0.862	ng/ml
value 2	1.08	1.51	3.01		0.381	ng/ml
Value 3	2.18	2.04	1.23		0.237	ng/ml
Value 4	1.37	0.695	1.21		0.985	ng/ml

G. GH (growth hormone) in OGGT (oral glucose tolerance test) before and after neurosurgery

December 2020					
Time (minutes)	0'	30'	60'	90'	120'
GH (ng/ml)	1.39	1.24	1.09	1.04	1.14
glucose (mg/dl)	87	159	153	NA	144
March 2021					
Time (minutes)	0'	30'	60'	90'	120'
GH (ng/ml)	1.63	1.5	0.789	0.695	0.674
glucose (mg/dl)	83	168	194	NA	110
July 2021					
Time (minutes)	0'	30'	60'	90'	120'
GH (ng/ml)	1.21	1.22	0.953	0.798	0.823
glucose (mg/dl)	76	148	125	NA	76
July 2021: trans-sphenoidal hypophysectomy of the adenoma (immunohistochemistry report with positive GH, chromogranin A, and a Ki 67 proliferation marker of 3%, and p 53 of less than 1%.					
August 2021					
Time (minutes)	0'	30'	60'	90'	120'
GH (ng/ml)	0.985	0.766	0.119	0.0779	0.069
glucose (mg/dl)	145.9	178.7	147.8	NA	58

Other investigations

Thyroid ultrasound showed a right thyroid lobe of 1.8 by 2 by 4.8 cm (centimeter), an isthmus of 0.4 cm, a left thyroid lobe of 1.8 by 1.7 by 4.5 cm, with inhomogeneous pattern, as well as a hypoechoic nodule at the level of right thyroid nodule of 0.6 by 0.5 by 0.6 cm. Central DXA (dual-energy X-ray absorptiometry) was within normal levels; TBS (trabecular bone score) was mildly reduced (Table 3).

TABLE 3. Central DXA on post-menopausal acromegalic woman (BMD = bone mineral density; TBS = trabecular bone score)

DXA regions	BMD (g/cm ²)	T-score (SD)	Z-score (SD)
lumbar 1-4	1.048	-1	-0.1
femoral neck	1.09	0.4	1.4
total hip	1.233	1.8	2.5

Follow-up

Post-operative success of acromegaly neurosurgery requires (anyway) a subsequent long term follow-up of the patient.

DISCUSSION

Three aspects worth to be mentioned in relationship with this case. First is the early detection of the disease at the moment when clinical examination was not suggestive for acromegaly. Thus early intervention was feasible. The remission of GH excess after neurosurgery depends on tumor size and practical experience of the neurosurgeon/center (5,6). The easy access

to cerebral and pituitary imaging techniques like computed tomography or magnetic resonance imaging allows premature revealing of a somatotropinoma nowadays (7,8). The patient we introduced had an association of other benign endocrine tumor at the level of uterus, stomach, etc. These tumors may be incidental or due to GH/IGF1 excess or they share a common genetic backup with the pituitary adenoma as seen in multiple endocrine neoplasia type 1 etc. (9,10). Also, The lady had a high level of bone resorption marker CrossLaps in addition to increased serum bone formation marker P1NP and a mild deficiency of vitamin D which was replaced with daily 1000 UI/ day. Acromegaly may cause a higher fracture risk especially at vertebral level; false positive normal DXA results due to arthrosis might be found (11,12,13). Acromegalic subjects may display a lower TBS (as seen here) due to GH/IGF1 – related bone quality impairment; bone turnover markers as well as bone quality are expected to improve once the GH/IGF-1 levels are controlled (14,15,16).

CONCLUSIONS

Awareness of health practitioners of different specialties including family physicians is essential for an early diagnostic of a GH secreting tumor before the traditional phenotype is registered. Early management means a major risk reduction of associated co-morbidities.

REFERENCES

- Ganokroj P, Sunthornyothin S, Siwanuwat R, Chantra K, Buranasupkajom P, Suwanwalaikorn S, Snabboon T. Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand. *Pan Afr Med J*. 2021 Sep 10;40:31.
- Albare F, Elaraki F, Delemer B. Daily life, needs and expectations of patients with acromegaly in France: An on-line survey. *Ann Endocrinol (Paris)*. 2019 Apr; 80(2):110-116.
- Zarool-Hassan R, Conaglen HM, Conaglen JV, Elston MS. Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners. *J Prim Health Care*. 2016 Jun;8(2):157-63.
- Valea A, Ghervan C, Carsote M, Morar A, Iacob I, Tomesc F, Po DD, Georgescu C. Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly. *Clujul Medical*. 2015;88(3):310-313.
- Dutta P, Hajela A, Pathak A, Bhansali A, Radotra BD, et al. Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. *Neurol India*. 2015 May-Jun;63(3):360-8.
- Akoglu G, Metin A, Emre S, Ersoy R, Cakir B. Cutaneous findings in patients with acromegaly. *Acta Dermatovenerol Croat*. 2013;21(4):224-9.
- Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly-advances in diagnosis and treatment. *Nat Rev Endocrinol*. 2012 Oct;8(10):605-11.
- Borgen AE, Bugge ABD, Lund EL, Banner J. Undiagnosed acromegaly as an underlying cause of sudden death. *Forensic Sci Med Pathol*. 2021 Jun;17(2):322-326.
- Cardinal T, Rutkowski MJ, Micko A, Shiroishi M, Jason Liu CS, Wrobel B, Carmichael J, Zada G. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly. *Neurosurg Focus*. 2020 Jun;48(6):E10.
- Ioachimescu AG. Acromegaly: achieving timely diagnosis and improving outcomes by personalized care. *Curr Opin Endocrinol Diabetes Obes*. 2021 Aug 1;28(4):419-426.
- Carsote M, Ghemigian A, Valea A, Dumitrascu A. Acromegaly – related osteoporosis. *Romanian Journal of Clinical Research*. 2018;1(1):27-30.
- Carrone F, Ariano S, Piccini S, Milani D, Mirani M, Balzarini L, Lania AG, Mazziotti G. Update on vertebral fractures in pituitary diseases: from research to clinical practice.

- Hormones* (Athens). 2021 Sep; 20(3):423-437.
13. Cellini M, Biamonte E, Mazza M, Trenti N, Ragucci P, Milani D, Ferrante E, et al. Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology. *Neuroendocrinology*. 2021;111(8):775-785.
14. Godang K, Olarescu NC, Bollerslev J, Heck A. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. *Eur J Endocrinol*. 2016 Aug;175(2):155-64.
15. Calatayud M, Pérez-Olivares Martín L, Librizzi MS, Lora Pablos D, González Méndez V, Aramendi Ramos M, Martínez Diaz-Guerra G, Hawkins F. Trabecular bone score and bone mineral density in patients with long-term controlled acromegaly. *Clin Endocrinol (Oxf)*. 2021 Jul;95(1):58-64.
16. Kužma M, Killinger Z, Jackuliak P, Vaňuga P, Hans D, Binkley N, Payer J. Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. *Physiol Res*. 2019 Nov 30;68(Suppl 2):S121-S129.